Skip to content

Clinical trials

Phase 2 Triple Negative Breast Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Triple Negative Breast Neoplasms Phase: Phase 2 Country / region: United States Clear all

189 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20072
20082
20093
20107
20115
20128
20134
20146
201512
201612
201721
201814
201916
202013
202116
20229
20236
202410
20258
202614

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed63
Recruiting37
Terminated37
Active, not recruiting29
Unknown status9
Withdrawn7
Not yet recruiting7

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center13
National Cancer Institute (NCI)11
Memorial Sloan Kettering Cancer Center7
Dana-Farber Cancer Institute5
University of Washington5
Emory University4
Merck Sharp & Dohme LLC4
UNC Lineberger Comprehensive Cancer Center4
University of Wisconsin, Madison4
City of Hope Medical Center3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Triple Negative Breast Neoplasms189
Breast Neoplasms109
Carcinoma, Non-Small-Cell Lung12
Brain Neoplasms8
Inflammatory Breast Neoplasms8
Neoplasm Metastasis8
Breast Neoplasms, Male7
Ovarian Neoplasms7
Stomach Neoplasms6
Carcinoma, Renal Cell5

Trials

Showing 1 to 25 of 189. Each trial links to its page on Pharma Observatory.

89 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.